

# Retrospective chart review of FreeStyle Libre in adults with type 2 diabetes using pre-mixed insulin

<b>Submission date</b> 13/01/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 27/01/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 12/02/2025	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Diabetes is a lifelong condition where the amount of sugar in the blood is too high. The aim of this study is to review the effectiveness of the FreeStyle Libre Glucose Monitoring System in adults with Type 2 diabetes using pre-mix insulin.

### Who can participate?

Patients aged 18 years or older, with type 2 diabetes

### What does the study involve?

For each medical record, HbA1c (a measure of average blood glucose) will be collected after 3 to 6 months of use of the FreeStyle Libre and compared with HbA1c from before starting FreeStyle Libre.

### What are the possible benefits and risks of participating?

There are no risks or direct benefits to patients whose medical records are included.

### When is the study starting and how long is it expected to run for?

June 2024 to June 2025

### Who is funding the study?

Abbott Diabetes Care Ltd

### Who is the main contact?

Dr Pamela Reid, [pamela.reid@abbott.com](mailto:pamela.reid@abbott.com)

## Contact information

### Type(s)

Public, Scientific

**Contact name**

Dr Pamela Reid

**Contact details**

Range Road  
Witney  
United Kingdom  
OX290YL  
+44 (0)1993 863024  
pamela.reid@abbott.com

**Type(s)**

Principal investigator

**Contact name**

Dr Thinzar Min

**Contact details**

Room 111, Diabetes Research Unit  
Swansea University Medical School  
Port Talbot  
United Kingdom  
SA2 8QA  
+44 (0)1639 862596  
Thinzar.min@wales.nhs.uk

## **Additional identifiers**

**Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

350006

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

ADC-UK-PMS-24060, CPMS 65134

## **Study information**

**Scientific Title**

A retrospective, non-interventional, chart review study of the effectiveness of FreeStyle Libre in adults with type 2 diabetes using pre-mixed insulin

**Acronym**

REFER-PREMIX

**Study objectives**

Effectiveness of FreeStyle Libre Glucose Monitoring Systems on glycaemic control versus standard of care measured by HbA1c, using patient records

### **Ethics approval required**

Ethics approval not required

### **Ethics approval(s)**

This is a retrospective observational study reviewing medical charts, which does not require ethics approval. The NHS HRA and UKRI Medical Research Council NHS REC checklist demonstrated that REC review is not required for England and Wales for this study, although the study was submitted and granted HRA and Health and Care Research Wales (HCRW) Approval.

### **Study design**

Retrospective non-interventional chart review study

### **Primary study design**

Observational

### **Study type(s)**

Other

### **Health condition(s) or problem(s) studied**

Type 2 diabetes mellitus (diabetes)

### **Interventions**

For each medical record, HbA1c (a measure of average blood glucose) will be collected after 3 to 6 months of use of the FreeStyle Libre and compared with HbA1c from before starting FreeStyle Libre.

### **Intervention Type**

Other

### **Primary outcome(s)**

Change in HbA1c from baseline to 3 to 6 months after initiation of FreeStyle Libre measured using patient records

### **Key secondary outcome(s))**

There are no secondary outcome measures

### **Completion date**

30/06/2025

## **Eligibility**

### **Key inclusion criteria**

1. Age 18 years or over at the time of starting a FreeStyle Libre system
2. Has type 2 diabetes using pre-mixed insulin only or pre-mixed insulin in combination with oral and/or injectable (non-insulin) medications for at least 1 year prior to starting a FreeStyle Libre system
3. Has used a FreeStyle Libre system regularly for at least 3 months

4. HbA1c recorded in medical notes between 8.0% and 12.0% (64 to 108 mmol/mol) in the 3 months prior to starting a FreeStyle Libre system
5. HbA1c recorded in medical notes 3 to 6 months after starting a FreeStyle Libre system

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Has used bolus or basal insulin during the data collection period
2. Female participant who was pregnant during the data collection period
3. Received dialysis treatment during the data collection period
4. Participated in another medical device or drug study that, in the Investigator's opinion, could have affected glucose measurements or management during the data collection period

**Date of first enrolment**

15/01/2025

**Date of final enrolment**

30/06/2025

**Locations****Countries of recruitment**

United Kingdom

England

Wales

**Study participating centre**

Swansea Bay University LHB

Port Talbot

United Kingdom

SA12 7BR

**Study participating centre**  
**Cardiff & Vale University LHB**  
Cardiff  
United Kingdom  
CF14 4HH

**Study participating centre**  
**County Durham and Darlington FT**  
Darlington  
United Kingdom  
DL3 6HX

**Study participating centre**  
**Hywel Dda University LHB**  
St Davids Park  
Carmarthen  
United Kingdom  
SA31 3BB

**Study participating centre**  
**Aneurin Bevan University LHB**  
Newport  
United Kingdom  
NP18 3XQ

**Study participating centre**  
**Middleton and Dinsdale Medical Practice**  
Darlington  
United Kingdom  
DL2 1BY

**Study participating centre**  
**Royal Glamorgan Hospital (CWM TAF MORG UNI LHB)**  
Llantrisant  
United Kingdom  
CF72 8TA

**Sponsor information**

**Organisation**  
Abbott Diabetes Care

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Abbott Diabetes Care

**Alternative Name(s)**

**Funding Body Type**  
Private sector organisation

**Funding Body Subtype**  
For-profit companies (industry)

**Location**  
United States of America

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Pamela Reid (pamela.reid@abbott.com).

All study data sourced for this study comes directly from data recorded in medical charts, so can be obtained from the original source via appropriate approval, rather than from the sponsor.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes